Skip to main content
. 2023 Oct 19;24:214. doi: 10.1186/s12875-023-02169-4

Table 1.

Comparison of demographic, clinical, anthropometric, and metabolic characteristics of the participants at baseline

Characteristic All study participants (n = 207) Metformin only (n = 78, 37.7%) Metformin and sulfonylurea (n = 129, 62.3%)
Age (years) 49 (40–57) 50 (43–57) 49 (39–57)
Gender
 1. Male 101 (48.8) 37 (47.4) 55 (42.6)
 2. Female 106 (51.2) 41 (52.6) 74 (57.4)
BMI (kg/m2) 27.5 (24.3–31.6) 27.2 (24.2–31.9) 27.7 (24.1–31.3)
WC (cm) 96.5 (89.0–104.0) 96.8 (88–106.4) 96.5 (89.0–104.0)
WHR 0.93 (0.89–0.96) 0.92 (0.89–0.97) 0.94 (0.90–0.96)
Systolic BP (mmHg) 127 (117–137) 128 (121–140) 125 (115–134)
Diastolic BP (mmHg) 84 (77–91) 87 (81–93) 82 (75–89)
HbA1c (%) 10.7 (8.3–12.3) 10.2 (8.3–12.3) 10.9 (8.4–12.5)
HbA1c (mmol/mol) 93 (67–111) 88 (67–111) 95 (68–113)
FBG (mmol/l) 8.6 (6.5–12.8) 8.8 (6.9–13.4) 8.2 (6.1–11.8)
Fasting insulin (µmol/l) 5.6 (3.2–10.0) 6.0 (3.6–10.0) 5.2 (3.0–9.6)
Fasting C-peptide (ng/ml) 1.4 (0.9–2.0) 1.4 (0.8–1.9) 1.3 (0.9–2.0)
Total cholesterol (mmol/l) 4.0 (3.2–5.0) 4.2 (3.2–5.3) 3.9 (3.2–4.9)
LDLC (mmol/l) 2.5 (1.9–3.5) 2.6 (2.0–3.6) 2.6 (1.9–3.5)
HDLC (mmol/l) 0.9 (0.7–1.2) 1.0 (0.8–1.2) 0.8 (0.7–1.1)
TGL (mmol/l) 1.5 (1.0–1.9) 1.5 (1.1–2.0) 1.4 (1.0–1.9)
Non-HDLC (mmol/l) 3.0 (2.3–4.0) 3.2 (2.2–4.3) 3.0 (2.4–3.8)
TC/HDLC 4.6 (3.6–5.5) 4.4 (3.6–5.1) 4.6 (3.7–5.6)
HOMA2-IR 1.1 (0.7–1.8) 1.1 (0.7–2.1) 1.1 (0.7–1.7)
HOMA2-%B 43.3 (21.6–69.2) 40.1 (15.7–57.9) 44.5 (24.6–70.5)

BMI Body mass index, BP Blood pressure, FBG Fasting blood glucose, HbA1c Glycated haemoglobin, HDLC High-density lipoprotein cholesterol, HOMA2-IR Homeostatic model assessment insulin resistance, HOMA2-%B Homeostatic model assessment pancreatic beta-cell function, LDLC low-density lipoprotein cholesterol, TC total cholesterol, TGL triglycerides, TC/HDLC total cholesterol: high-density lipoprotein cholesterol ratio, WC waist circumference, WHR waist: hip circumference ratio